Glenmark Pharmaceuticals Limited Q1 Profit Rises 928% YoY

Glenmark Pharmaceuticals Limited reported consolidated net profit of ₹482.82 crore for the quarter ended June 30, 2026, a 927.93% increase year-on-year, as revenue rose 23.10% to ₹4,018.48 crore and operating profit more than doubled sequentially.

What did Glenmark report for Q1 FY27?

Glenmark reported revenue of ₹4,018.48 crore in Q1 FY27, compared with ₹3,264.4 crore in the corresponding quarter of the previous year. The reported revenue was also 6.57% higher than the ₹3,770.59 crore recorded in Q4 FY26. The company’s June-quarter performance showed growth across India, North America, Europe and emerging markets, with the company attributing the broad momentum to product launches and execution.

Net profit came in at ₹482.82 crore, against ₹47 crore in Q1 FY26. The sharp year-on-year percentage increase partly reflects the relatively low profit base in the year-earlier quarter. On a sequential basis, profit rose 60.24% from ₹301.31 crore in Q4 FY26. Earnings per share for the quarter stood at ₹17.11, compared with ₹1.66 in Q1 FY26.

The company’s operating profit was ₹804.79 crore, up 38.6% from ₹580.66 crore a year earlier and 106.78% from ₹389.20 crore in the preceding quarter. Its reported EBITDA margin improved to 20.03% from 17.79% a year earlier, an expansion of 224 basis points.

Which financial metrics improved during the quarter?

The main financial metrics improved across revenue, operating profit, profit before depreciation and tax, profit before tax and net profit. Profit before depreciation and tax was ₹816.55 crore, increasing 52.44% sequentially from ₹535.67 crore and 262.11% from the year-earlier period.

Profit before tax reached ₹643.38 crore, compared with ₹387.76 crore in Q4 FY26, a sequential rise of 65.92%. It was 573.20% higher year-on-year. The progression from revenue growth to operating profit and net profit indicates a stronger quarterly operating outcome than the preceding quarter, while the margin expansion provides context for the increase in profitability.

What drove Glenmark's revenue growth across markets?

Glenmark said India, North America, Europe and emerging markets delivered double-digit revenue growth in the June 2026 quarter. The company linked this performance to new product launches and execution. The supplied results do not provide region-wise revenue figures or separate growth rates, so the precise contribution from each geography is not disclosed.

The India business is expected by the company to sustain annual growth of 12% to 15%, supported by volume growth and new product launches. This outlook is relevant because the domestic business remains one part of Glenmark’s broader multi-market operating model. The Q1 result also reflects that growth was reported across several geographies rather than being described as a single-market development.

Why does the margin expansion matter for investors?

The EBITDA margin increase to 20.03% from 17.79% is significant because revenue growth alone does not explain the full change in quarterly earnings. Operating profit rose faster than revenue on a year-on-year basis, while net profit reached ₹482.82 crore. Together, these figures show that the June-quarter result included an improvement in reported operating profitability.

Comparisons with the previous year should nevertheless account for base effects. Net profit of ₹47 crore in Q1 FY26 was substantially lower than the latest quarter’s ₹482.82 crore, producing the reported 927.93% increase. Similarly, Glenmark’s Q4 FY26 net profit of ₹301 crore was sharply higher than ₹4 crore in Q4 FY25, also because of a low base. The absolute profit, margin and revenue figures therefore provide important context alongside percentage growth rates.

Glenmark’s reported trailing 12-month return on invested capital was 30.6% in Q1 FY27, compared with a stated cost of capital of 12%. These measures are reported financial indicators, but the supplied data does not provide a comparable return-on-capital figure for prior periods.

What should investors monitor in Glenmark's September-quarter results?

Investors will monitor Glenmark’s July to September 2026 results for evidence that revenue growth and profitability remain supported by product launches and performance across its key geographies. The Board of Directors was scheduled to meet on November 5, 2026, to consider and approve unaudited standalone and consolidated results for the quarter and half-year ended September 30, 2026.

Respiratory product approvals are another disclosed item to track. At least two of three pending respiratory products, including Fluticasone 110 mcg and Ipratropium, are expected to receive approval in the second half of FY27. Fluticasone 44 mcg was expected to make a full-quarter contribution during July to September 2026. The source does not state whether these approvals had been received or quantify their financial contribution.

The timing of the Q2 disclosure is also material for investors following the company’s operating trajectory. Listed companies are generally required to publish quarterly results within 45 days of a quarter-end, except for the January to March quarter, for which the deadline is 60 days. Glenmark had identified November 5, 2026 as its upcoming earnings date.

Conclusion

Glenmark’s Q1 FY27 results showed revenue growth of 23.10% to ₹4,018.48 crore, operating profit of ₹804.79 crore and net profit of ₹482.82 crore. The margin improvement and higher profits were accompanied by double-digit revenue growth across the company’s stated major markets, although the reported percentage rise in net profit should be read alongside the low year-earlier base.

The next disclosed milestone is the Board meeting scheduled for November 5, 2026 to consider the September-quarter and half-year results. Investors will also watch the status of the pending respiratory product approvals and whether Fluticasone 44 mcg contributed through the July to September quarter as anticipated.